Madrigal Pharmaceuticals, Inc. clinical trials

The registry lists 46 studies whose lead sponsor is Madrigal Pharmaceuticals, Inc. or one of 1 company grouped under it. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 16, 2026.

Studies

Recruiting first, then most recently updated. Showing 46 of 46.

• Resmetirom in Patients With MASH and HFpEFRecruitingNCT07830758Phase 1
• Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisRecruitingNCT07848191Phase 4
• Study of Resmetirom in Children and Adolescents With MASHRecruitingNCT07763015Phase 2
• Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHRecruitingNCT07335601Phase 2
• Rezdiffra Pregnancy and Lactation RegistryRecruitingNCT07541469
• A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)Active, not recruitingNCT05500222Phase 3
• Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)CompletedNCT03038022Phase 2
• A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisActive, not recruitingNCT03900429Phase 3
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)Active, not recruitingNCT04951219Phase 3
• Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT02912260Phase 2
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal FunctionCompletedNCT06397872Phase 1
• Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control SubjectsCompletedNCT04643795Phase 1
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease PatientsCompletedNCT04197479Phase 3
• Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy SubjectsCompletedNCT01367873Phase 1
• Drug Interaction Study of MGL-3196 With Rosuvastatin and SimvastatinCompletedNCT02542969Phase 1
• Drug Interaction Study of MGL-3196 With ClopidogrelCompletedNCT04671069Phase 1
• Drug Interaction Study of MGL-3196 With PioglitazoneCompletedNCT04671056Phase 1
• Bioavailability Study of MGL-3196 Tablets Compared to CapsulesCompletedNCT03413124Phase 1
• Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196CompletedNCT03220165Phase 1
• Drug Interaction Study of MGL-3196 With AtorvastatinCompletedNCT02749578Phase 1
• A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLCTerminatedNCT01798485Phase 3

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)CompletedNCT01039519Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung CancerTerminatedNCT01348126Phase 2/3

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast CancerCompletedNCT01677455Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT01562015Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01031225Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid TumorsCompletedNCT01183364Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous LeukemiaCompletedNCT00964873Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative DisordersCompletedNCT00858572Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• Study of STA-9090, Administered Once-Weekly in Patients With Solid TumorsCompletedNCT00687934Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• Study of STA-9090, Administered Twice-Weekly in Patients With Solid TumorsStatus unknownNCT00688116Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• STA-4783 and Paclitaxel for Treatment of Solid TumorsCompletedNCT00088114Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• STA-4783/Paclitaxel or Paclitaxel Alone in MelanomaCompletedNCT00084214Phase 1/2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in MelanomaTerminatedNCT00522834Phase 3

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue OutcomesCompletedNCT00642629Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid LeukemiaStatus unknownNCT01280786Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate CancerCompletedNCT00808418Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid TumorsCompletedNCT00276913Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy SubjectsCompletedNCT01519531Phase 1
• A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid TumorsSuspendedNCT00827203Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's DiseaseCompletedNCT00138840Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid TumorsCompletedNCT00088101Phase 1

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's DiseaseCompletedNCT00234741Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)CompletedNCT00088088Phase 1/2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue SarcomasCompletedNCT00087997Phase 2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.

• STA-5326 in Crohn's Disease PatientsCompletedNCT00088062Phase 1/2

  Sponsor listed in the registry: Synta Pharmaceuticals Corp. · First submitted before Synta Pharmaceuticals Corp. became part of Madrigal Pharmaceuticals, Inc.